Protara Therapeutics CFO Blaine Davis to depart July 15, 2022

Protara Therapeutics, Inc.

CFO Blaine Davis leaving to pursue other opportunities, effective July 15, 2022; resignation not due to disagreements.
Separation agreement: 12-month base salary lump sum, target bonus, COBRA and life insurance premiums, accelerated equity vesting.
Company had $119M cash, cash equivalents and investments as of March 31, 2022, expected to fund operations into mid-2024.
CEO Jesse Shefferman thanked Davis for building finance, commercial, and IT functions.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Blaine Davis

Chief Financial Officer

TARA · Protara Therapeutics, Inc.

Effective: 2022-07-15
Filed: June 21, 2022, 7:59 PM ET

On June 21, 2022 Protara Therapeutics, Inc. (the “Company”) announced that Blaine Davis, Chief Financial Officer of the Company, will be leaving the Company to pursue other opportunities effective as of July 15, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Blaine Davis departed as Chief Financial Officer at Protara Therapeutics, Inc..

Action: leaving
Role: Chief Financial Officer

Exact text from the filing

On June 21, 2022 Protara Therapeutics, Inc. (the “Company”) announced that Blaine Davis, Chief Financial Officer of the Company, will be leaving the Company to pursue other opportunities effective as of July 15, 2022.

View on SEC.gov

Protara Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-22-033756

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.